Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies

• Published in: Journal of gastrointestinal cancer 2024-09, Vol.55 (3), p.1144-1153
• Main Authors: Li, Ju, Wang, Wanqing, Jiang, Kaipeng, Cui, Jiuwei, Wang, Chang, Liang, Tingting, Wang, Yizhuo, Liu, Shuhan, Zhou, Wenshuo
• Format: Article
• Language: English
• Subjects: Cancer Research; Gastroenterology; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Radiotherapy
• ISSN: 1941-6628; 1941-6636; 1941-6636
• DOI: 10.1007/s12029-024-01059-x

Purpose Thrombocytopenia is among the most common chemotherapy-related hematologic toxicities. We aim to determine the predictors of oxaliplatin chemotherapy-induced thrombocytopenia in patients with gastrointestinal tumors to guide the clinic. Methods Clinical data of 750 patients with a malignant gastrointestinal tumor were included as the primary cohort. Basic clinical data, serological indices, and anthropometric indices of these patients were collected. According to the presence or absence of CIT, univariate analysis was performed to identify significant factors for multivariate analysis. In R language software, nomogram was constructed based on the results of multi-factor analysis, and the calibration curve and ROC curve were drawn. Results Univariate analysis identified 17 factors as closely related to CIT occurrence, namely age, lymph node metastasis (N) stage, metastasis (M) stage, lung metastasis, other site metastasis, chemotherapy regimen, course of treatment, total dose of oxaliplatin, AST, albumin, neutrophils, monocytes, baseline platelets, transferrin, natural killer (NK) cell, phase angle, and SMI ( P